A negative survival trend and design flaws in the lone pivotal trial for Aveo Pharmaceuticals Inc.’s tivozanib outweighed the statistically significant progression-free survival benefit seen with the renal cell carcinoma drug, an FDA advisory committee said May 2.
FDA’s Oncologic Drugs Advisory Committee voted 13-1 that Aveo failed to demonstrate a favorable benefit/risk evaluation for treatment of renal...